Pharma Sector

View this page in: Spanish

In addition to the issues common to other sectors, we address specific sector issues, including:

Advice on drug registration, authorisation and financing
Advice on function outsourcing.
Tax optimisation of R&D incentives and public assistance.
Human capital: talent retention programmes, flexible compensation systems, equality programmes, codes of conduct .
Tax optimisation of the value chain: transfer pricing policy and management of intangibles.
Foundations.
Advice on acquisitions, due diligence, product licensing, cost sharing agreements.
Compliance with data protection legislation in relations with patients taking part in clinical trials.
Issues concerning VAT rates on healthcare products.

SECTORS

Contact

Rafael Rodríguez: Pharma Sector Landwell PwC partner.; Contact

More information

PwC Sectors
Pharma 2020: Marketing the future (2009) (PDF 932KB)
Pharma 2020: Virtual R&D - Which path will you take? (PDF 400KB)
Pharma 2020: The vision - Which path will you take? (PDF 710KB)

© 2010 PricewaterhouseCoopers. All rights reserved.
"PricewaterhouseCoopers" and "PwC" refer to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL). Each member firm is a separate legal entity and does not act as agent of PwCIL or any other member firm. PwCIL does not provide any services to clients. PwCIL is not responsible or liable for the acts or omissions of any of its member firms nor can it control the exercise of their professional judgment or bind them in any way.
No member firm is responsible or liable for the acts or omissions of any other member firm nor can it control the exercise of another member firm's professional judgment or bind another member firm or PwCIL in any way.